The qualitative and quantitative research issues of lay and expert panel prototype-to-phenotype development will be presented, with implications for phenotyping other gene-environment health-related behaviors of research and clinical interest. Characteristic smoking behaviors are difficult to describe and classify systematically (e.g., smokers with depressive symptoms, chain smokers). Because smoking is likely influenced by gene-environment interaction, per the adapted Schmidt, et al. (2000) Risk Factor Model, smoking behaviors can be viewed as smoking phenotypes. One theoretically sampled Lay Expert Panel (n=7) and one Provider Expert Panel (n=4) generated prototypes among Caucasian, non-Hispanics (5 and 8 pharmacological and non-pharmacological prototypes, respectively). The Provider Panel used the prototypes, literature-based evidence tables,and their expertise to identify the defining characteristics of 4 phenotypes. Phenotype validity assessments include Adjusted Kappa. The outcome will be several smoking phenotypes among Caucasian non-Hispanics. Once validated, precise clinical smoking phenotype definitions can focus on risk assessment, tailoring of smoking interventions, and development of pharmacotherapies based on smoking-related genes. Funding: Nebraska Health and Human Services, Grant 2001-01B.
Learning Objectives: 1. Describe the interaction of gene-environment on smoking behavior, per the Schmidt, et al. (2000) Risk Factor Model. 2. Articulate the researchers' quantitative and qualitative methods used to refine the emergent classifications of smokers, including the use of Lay Panels and Provider Panels. 3. Identify current literature relevant to the classification of Caucasian, non-Hispanic data on smoking phenotypes. 4. Identify the study's findings for clinical smoking phenotypes of adults smokers. 5. Discuss the implications of the presentation's strategy for phenotype development in risk assessment, nursing interventions, pharmacotherapies, and genotyping.
Keywords: Smoking, Methodology
Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: cigarettes (no brand )
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.